重视慢性移植物抗宿主病的临床管理

冯一梅; 张曦

doi:10.13201/j.issn.1004-2806.2019.09.001

重视慢性移植物抗宿主病的临床管理

冯一梅,
张曦^,

- 陆军军医大学新桥医院血液病医学中心, 全军血液病中心, 创伤、烧伤、复合伤国家重点实验室(重庆, 400037)
基金项目:
国家自然科学基金(No:81400081、81873424)

国家重点研究计划(No:2017YFA0105502)

重庆市社会事业与民生保障科技创新专项(No:cstc2016shmsztzx10003)

第三军医大学第二附属医院学科交叉合作项目(No:2016D413)

军队重大课题专项(No:AWS14C014)

详细信息

通讯作者: 张曦,E-mail:Zhangxxi@sina.com

中图分类号: R457.7

收稿日期: 2019-07-01

Clinical management of chronic graft-versus-host disease

FENG Yimei,
ZHANG Xi^,

More Information

Corresponding author: ZHANG Xi, E-mail: Zhangxxi@sina.com

Received Date: 01 July 2019

摘要

- 异基因造血干细胞移植 /
- 慢性移植物抗宿主病 /
- 临床管理
- allogeneic hematopoietic stem cell transplantation /
- chronic graft-versus-host disease /
- clinical man-agement

HTML全文

参考文献(29)

[1]	Sarantopoulos S,Cardones AR,Sullivan KM.How I treat refractory chronic graft-versus-host disease[J].Blood,2019,133:1191-1200.
[2]	Mays JW,Fassil H,Edwards DA,et al.Oral chronic graft-versus-host disease:current pathogenesis,therapy,and research[J].Oral Dis,2013,19:327-346.
[3]	Zhou H,Guo M,Bian C,et al.Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease:clinical report[J].Biol Blood Marrow Transplant,2010,16:403-412.
[4]	Jagasia MH,Greinix HT,Arora M,et al.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease:I.The 2014 Diagnosis and Staging Working Group report[J].Biol Blood Marrow Transplant,2015,21:389-401.e1.
[5]	Khandelwal P,Mellor-Heineke S,Rehman N,et al.Cytokine profile of engraftment syndrome in pediatric hematopoietic stem cell transplant recipients[J].Biol Blood Marrow Transplant,2016,22:690-697.
[6]	Arora M,Klein JP,Weisdorf DJ,et al.Chronic GVHD risk score:a Center for International Blood and Marrow Transplant Research analysis[J].Blood,2011,117:6714-6720.
[7]	Moon JH,Hamad N,Sohn SK,et al.Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD[J].Ann Hematol,2017,96:805-815.
[8]	Pidala J,Vogelsang G,Martin P,et al.Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis,functional impairment,and inferior patient-reported outcomes:a Chronic Graft-versus-Host Disease Consortium study[J].Haematologica,2012,97:451-458.
[9]	Socie G,Ritz J.Current issues in chronic graft-versus-host disease[J].Blood,2014,124:374-384.
[10]	Li X,Gao Q,Feng Y,et al.Developing role of B cells in the pathogenesis and treatment of chronic GVHD[J].Br J Haematol,2019,184:323-236.
[11]	Berger M,Albiani R,Sini B,et al.Extracorporeal photopheresis for graft-versus-host disease:the role of patient,transplant,and classification criteria and hematologic values on outcome-results from a large single-center study[J].Transfusion (Paris),2015,55:736-747.
[12]	Nagler A,Menachem Y,Ilan Y.Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment[J].J Hematother Stem Cell Res,2001,10:411-417.
[13]	Olivieri A,Cimminiello M,Corradini P,et al.Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD[J].Blood,2013,122:4111-4118.
[14]	Jedlickova Z,Burlakova I,Bug G,et al.Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors[J].Biol Blood Marrow Transplant,2011,17:657-663.
[15]	Gao L,Zhang Y,Hu B,et al.Phase II Multicenter,Randomized,Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation[J].J Clin Oncol,2016,34:2843-2850.
[16]	Kharfan-Dabaja MA,Mhaskar AR,Djulbegovic B,et al.Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease:a systematic review and meta-analysis[J].Biol Blood Marrow Transplant,2009,15:1005-1013.
[17]	Teachey DT,Bickert B,Bunin N.Daclizumab for children with corticosteroid refractory graft-versus-host disease[J].Bone Marrow Transplant,2006,37:95-99.
[18]	Ruiz-Arguelles GJ,Gil-Beristain J,Magana M,et al.Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease[J].Biol Blood Marrow Transplant,2008,14:7-9.
[19]	Shapira MY,Abdul-Hai A,Resnick IB,et al.Alefacept treatment for refractory chronic extensive GVHD[J].Bone Marrow Transplant,2009,43:339-343.
[20]	Motllo C,Ferra C,Lopez L,et al.Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients[J].Med Clin (Barc),2011,137:115-118.
[21]	Drobyski WR,Pasquini M,Kovatovic K,et al.Tocilizumab for the treatment of steroid refractory graft-versus-host disease[J].Biol Blood Marrow Transplant,2011,17:1862-1868.
[22]	Blazar BR,Murphy WJ,Abedi M.Advances in graft-versus-host disease biology and therapy[J].Nat Rev Immunol,2012,12:443-458.
[23]	McManigle W,Youssef A,Sarantopoulos S.B cells in chronic graft-versus-host disease[J].Hum Immunol,2019,80:393-399.
[24]	Ryan CE,Sahaf B,Logan AC,et al.Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT[J].Blood,2016,128:2899-2908.
[25]	Pai CC,Chen M,Mirsoian A,et al.Treatment of chronic graft-versus-host disease with bortezomib[J].Blood,2014,124:1677-1688.
[26]	Herrera AF,Kim HT,Bindra B,et al.A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease[J].Biol Blood Marrow Transplant,2014,20:1737-1743.
[27]	Flynn R,Paz K,Du J,et al.Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism[J].Blood,2016,127:2144-2154.
[28]	Lazaryan A,Lee SJ,Salhotra A,et al.Initial Results of KD025-208:A Phase 2a Open-Label Clinical Trial of KD025 for Steroid-Dependent Chronic Graft Versus Host Disease (cGVHD)[J].Biol Blood Marrow Transplant,2018,24:S48.
[29]	Wolff D,Schleuning M,von Harsdorf S,et al.Consensus Conference on Clinical Practice in Chronic GVHD:Second-Line Treatment of Chronic Graft-versus-Host Disease[J].Biol Blood Marrow Transplant,2011,17:1-17.